A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer

DSpace/Manakin Repository

A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer

Citable link to this page

 

 
Title: A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer
Author: Meyerhardt, Jeffrey A; Grady, Michele M; Lowe, Jamie N; Gargano, Michele A; Huhn, Richard D; Braun, Ada H

Note: Order does not necessarily reflect citation order of authors.

Citation: Meyerhardt, Jeffrey A, Michele M Grady, Jamie N Lowe, Michele A Gargano, Richard D Huhn, and Ada H Braun. 2014. “A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer.” Journal for Immunotherapy of Cancer 2 (Suppl 3): P71. doi:10.1186/2051-1426-2-S3-P71. http://dx.doi.org/10.1186/2051-1426-2-S3-P71.
Full Text & Related Files:
Abstract:
Published Version: doi:10.1186/2051-1426-2-S3-P71
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288729/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890586
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters